Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Research & Development: 2009-2024

Historic Research & Development for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $481.0 million.

  • UNITED THERAPEUTICS's Research & Development rose 23.19% to $127.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $544.3 million, marking a year-over-year increase of 9.17%. This contributed to the annual value of $481.0 million for FY2024, which is 17.89% up from last year.
  • UNITED THERAPEUTICS's Research & Development amounted to $481.0 million in FY2024, which was up 17.89% from $408.0 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Research & Development registered a high of $540.1 million during FY2021, and its lowest value of $322.9 million during FY2022.
  • Over the past 3 years, UNITED THERAPEUTICS's median Research & Development value was $408.0 million (recorded in 2023), while the average stood at $404.0 million.
  • In the last 5 years, UNITED THERAPEUTICS's Research & Development slumped by 69.75% in 2020 and then spiked by 50.99% in 2021.
  • Over the past 5 years, UNITED THERAPEUTICS's Research & Development (Yearly) stood at $357.7 million in 2020, then skyrocketed by 50.99% to $540.1 million in 2021, then crashed by 40.21% to $322.9 million in 2022, then grew by 26.35% to $408.0 million in 2023, then grew by 17.89% to $481.0 million in 2024.